+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetes Drugs Market Research Report by Application (Type 1 Diabetes and Type 2 Diabetes), by Drug Type (Injectable Drug and Oral Drug), by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4989870
  • Report
  • July 2021
  • Region: Global
  • 189 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Diabetes Drugs Market will Grow to USD 77.17 Billion by 2026, at a CAGR of 6.80%

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • Daiichi Sankyo
  • Merck & Co.
  • Novo Nordisk
  • Pfizer Inc.
The Global Diabetes Drugs Market size was estimated at USD 51.99 Billion in 2020 and expected to reach USD 55.35 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 6.80% to reach USD 77.17 Billion by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Diabetes Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Application, the Diabetes Drugs Market was examined across Type 1 Diabetes and Type 2 Diabetes.
  • Based on Drug Type, the Diabetes Drugs Market was examined across Injectable Drug and Oral Drug. The Injectable Drug was further studied across Aspart, Exenatide, Glargine, Insulin, Leraglutide, and Pramlintide. The Oral Drug was further studied across Alpha-glucosidase Inhibitors, Biguanides, DPP-4 Inhibitors, Meglitinides and D-Phenylalanine Derivatives, Sulfonylureas, and Thiazolidinediones.
  • Based on Geography, the Diabetes Drugs Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas was further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific was further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa was further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies this research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Diabetes Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Diabetes Drugs Market, including Abbott Laboratories, Akros Pharma, AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo, Eli Lilly and Company, Johnson & Johnson Services, Inc., Merck & Co., Novartis AG, Novo Nordisk, Peptron, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Company Limited.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Diabetes Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Diabetes Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Diabetes Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Diabetes Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Diabetes Drugs Market?
6. What is the market share of the leading vendors in the Global Diabetes Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Diabetes Drugs Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • Daiichi Sankyo
  • Merck & Co.
  • Novo Nordisk
  • Pfizer Inc.
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Application Outlook
3.4. Drug Type Outlook
3.5. Geography Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in prevalence of diabetes disease
5.1.1.2. Rise in obesity coupled with unhealthy diets and sedentary lifestyles
5.1.1.3. Surge in the number of programs to create health awareness
5.1.2. Restraints
5.1.2.1. Side-effects of drugs in certain cases
5.1.3. Opportunities
5.1.3.1. Advancements in diabetic medications by pharmaceutical manufacturers
5.1.3.2. Rising investment in healthcare and development of healthcare infrastructure
5.1.4. Challenges
5.1.4.1. Stringent regulatory environment and time-consuming approval process
5.1.4.2. Lack of awareness among patients towards the availability of drugs
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Diabetes Drugs Market, by Application
6.1. Introduction
6.2. Type 1 Diabetes
6.3. Type 2 Diabetes

7. Diabetes Drugs Market, by Drug Type
7.1. Introduction
7.2. Injectable Drug
7.2.1. Aspart
7.2.2. Exenatide
7.2.3. Glargine
7.2.4. Insulin
7.2.5. Leraglutide
7.2.6. Pramlintide
7.3. Oral Drug
7.3.1. Alpha-glucosidase Inhibitors
7.3.2. Biguanides
7.3.3. DPP-4 Inhibitors
7.3.4. Meglitinides and D-Phenylalanine Derivatives
7.3.5. Sulfonylureas
7.3.6. Thiazolidinediones

8. Americas Diabetes Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Diabetes Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Thailand

10. Europe, Middle East & Africa Diabetes Drugs Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Abbott Laboratories
12.2. Akros Pharma
12.3. AstraZeneca
12.4. Bayer AG
12.5. Boehringer Ingelheim International GmbH
12.6. Daiichi Sankyo
12.7. Eli Lilly and Company
12.8. Johnson & Johnson Services, Inc.
12.9. Merck & Co.
12.10. Novartis AG
12.11. Novo Nordisk
12.12. Peptron
12.13. Pfizer Inc.
12.14. Sanofi
12.15. Takeda Pharmaceutical Company Limited

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL DIABETES DRUGS MARKET SIZE, 2020 VS 2026 (USD BILLION)
FIGURE 2. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2020 (USD BILLION)
FIGURE 3. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2020 (USD BILLION)
FIGURE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD BILLION)
FIGURE 5. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 6. GLOBAL DIABETES DRUGS MARKET: MARKET DYNAMICS
FIGURE 7. GLOBAL DIABETES DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
FIGURE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD BILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2026
FIGURE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, 2018-2026 (USD BILLION)
FIGURE 12. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 13. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, 2018-2026 (USD BILLION)
FIGURE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 15. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2020 VS 2026 (%)
FIGURE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2020 VS 2026 (USD BILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2026
FIGURE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2026 (USD BILLION)
FIGURE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY ASPART, 2018-2026 (USD BILLION)
FIGURE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY ASPART, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 22. GLOBAL DIABETES DRUGS MARKET SIZE, BY EXENATIDE, 2018-2026 (USD BILLION)
FIGURE 23. GLOBAL DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 24. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLARGINE, 2018-2026 (USD BILLION)
FIGURE 25. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 26. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2026 (USD BILLION)
FIGURE 27. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 28. GLOBAL DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, 2018-2026 (USD BILLION)
FIGURE 29. GLOBAL DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 30. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, 2018-2026 (USD BILLION)
FIGURE 31. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 32. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2026 (USD BILLION)
FIGURE 33. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 34. GLOBAL DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, 2018-2026 (USD BILLION)
FIGURE 35. GLOBAL DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 36. GLOBAL DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2026 (USD BILLION)
FIGURE 37. GLOBAL DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 38. GLOBAL DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2026 (USD BILLION)
FIGURE 39. GLOBAL DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 40. GLOBAL DIABETES DRUGS MARKET SIZE, BY MEGLITINIDES AND D-PHENYLALANINE DERIVATIVES, 2018-2026 (USD BILLION)
FIGURE 41. GLOBAL DIABETES DRUGS MARKET SIZE, BY MEGLITINIDES AND D-PHENYLALANINE DERIVATIVES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 42. GLOBAL DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2026 (USD BILLION)
FIGURE 43. GLOBAL DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 44. GLOBAL DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2026 (USD BILLION)
FIGURE 45. GLOBAL DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 46. AMERICAS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 47. AMERICAS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 49. ARGENTINA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 50. BRAZIL DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 51. CANADA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 52. MEXICO DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 53. UNITED STATES DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 54. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 55. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 56. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 57. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 58. CHINA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 59. INDIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 60. INDONESIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 61. JAPAN DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 62. MALAYSIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 63. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 64. SINGAPORE DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 65. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 66. THAILAND DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 67. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 68. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 69. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 70. FRANCE DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 71. GERMANY DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 72. ITALY DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 73. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 74. QATAR DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 75. RUSSIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 76. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 77. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 78. SPAIN DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 79. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 80. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 81. GLOBAL DIABETES DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 82. GLOBAL DIABETES DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 83. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL DIABETES DRUGS MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL DIABETES DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY ASPART, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 12. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 13. GLOBAL DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 15. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 17. GLOBAL DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY MEGLITINIDES AND D-PHENYLALANINE DERIVATIVES, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 22. AMERICAS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 23. AMERICAS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 24. AMERICAS DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 25. ARGENTINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 26. ARGENTINA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 27. BRAZIL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 28. BRAZIL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 29. CANADA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 30. CANADA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 31. MEXICO DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 32. MEXICO DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 33. UNITED STATES DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 34. UNITED STATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 35. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 36. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 37. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 38. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 39. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 40. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 41. CHINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 42. CHINA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 43. INDIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 44. INDIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 45. INDONESIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 46. INDONESIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 47. JAPAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 48. JAPAN DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 49. MALAYSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 50. MALAYSIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 51. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 52. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 53. SINGAPORE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 54. SINGAPORE DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 55. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 56. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 57. THAILAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 58. THAILAND DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 62. FRANCE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 63. FRANCE DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 64. GERMANY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 65. GERMANY DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 66. ITALY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 67. ITALY DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 68. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 69. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 70. QATAR DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 71. QATAR DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 72. RUSSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 73. RUSSIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 74. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 75. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 76. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 77. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 78. SPAIN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 79. SPAIN DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 80. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 81. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 82. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD BILLION)
TABLE 83. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD BILLION)
TABLE 84. GLOBAL DIABETES DRUGS MARKET: SCORES
TABLE 85. GLOBAL DIABETES DRUGS MARKET: BUSINESS STRATEGY
TABLE 86. GLOBAL DIABETES DRUGS MARKET: PRODUCT SATISFACTION
TABLE 87. GLOBAL DIABETES DRUGS MARKET: RANKING
TABLE 88. GLOBAL DIABETES DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 89. GLOBAL DIABETES DRUGS MARKET: MERGER & ACQUISITION
TABLE 90. GLOBAL DIABETES DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 91. GLOBAL DIABETES DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 92. GLOBAL DIABETES DRUGS MARKET: INVESTMENT & FUNDING
TABLE 93. GLOBAL DIABETES DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 94. GLOBAL DIABETES DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Akros Pharma
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Merck & Co.
  • Novartis AG
  • Novo Nordisk
  • Peptron
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll